Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: A matched cohort study

Supportive Care in Cancer

Volumn 19, Issue 11, 2011, Pages 1815-1821

  Timilshina, Narhari ^a,b   Hussain, Shabbir ^a,b   Breunis, Henriette ^a,b   Alibhai, Shabbir M H ^b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aged; Androgen deprivation therapy; Anemia; Prostate cancer

Indexed keywords

HEMOGLOBIN;

AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; EDUCATION; FUNCTIONAL STATUS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; UNIVARIATE ANALYSIS;

ACTIVITIES OF DAILY LIVING; AGED; ANDROGEN ANTAGONISTS; CASE-CONTROL STUDIES; COHORT STUDIES; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 83255193406     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-1023-6     Document Type: Article

References (25)

1. Canadian Cancer Society (2009) Canadian cancer statistics 2009. Canadian Cancer Society, Toronto
2. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M (1996) Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 29:243-248
3. Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG et al (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 107:489-496
4. Bland JM, Altman DG (1994) Regression towards mean. Bmj 308:1499
5. Bylow K, Mohile SG, Stadler WM, Dale W (2007) Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer 110:2604-2613
6. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G et al (2005) Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 62:719-724
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383
8. Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G et al (2005) How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol 12:2547-2552
9. den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Assendelft WJ, Gussekloo J (2009) Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. Cmaj 181:151-157
10. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC (1998) Anemia after orchiectomy. Am J Hematol 59:230-233
11. Harrell FE Jr (2001) Multivariable modeling strategies. In: Harrell FE Jr (ed) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York, pp 53-86
12. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388-395
13. Holzbeierlein JM (2006) Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 33:181-190, vi
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225-249
15. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrument activities of daily living. Gerontologist 9:179-186
16. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS et al (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596-1605
17. Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61-65
18. Maraldi C, Volpato S, Cesari M, Cavalieri M, Onder G, Mangani I et al (2006) Anemia and recovery from disability in activities of daily living in hospitalized older persons. J Am Geriatr Soc 54:632-636
19. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR (1997) The national cancer data base report on race, age, and region variations in prostate cancer treatment. Cancer 80:1261-1266
20. Nalesnik JG, Mysliwiec AG, Canby-Hagino E (2004) Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol 6:1-4
21. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K (2005) The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90:657-660
22. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43-46
23. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
24. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933-941
25. Zarychanski R, Houston DS (2008) Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? Cmaj 179:333-337